#### Check for updates

#### OPEN ACCESS

EDITED BY Jianming Qiu, University of Kansas Medical Center, United States

REVIEWED BY Qiaozhen Ye, University of California, San Diego, United States Richard Adeyemi, Fred Hutchinson Cancer Center, United States

\*CORRESPONDENCE Thomas Dobner Momas.dobner@leibniz-liv.de

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 21 August 2024 ACCEPTED 16 September 2024 PUBLISHED 27 September 2024

#### CITATION

Ip W-H, Fiedler M, Gornott B, Morische M, Bertzbach LD and Dobner T (2024) Cellular SUMO-specific proteases regulate HAdV-C5 E1B-55K SUMOylation and virus-induced cell transformation. *Front. Cell. Infect. Microbiol.* 14:1484241. doi: 10.3389/fcimb.2024.1484241

#### COPYRIGHT

© 2024 Ip, Fiedler, Gornott, Morische, Bertzbach and Dobner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Cellular SUMO-specific proteases regulate HAdV-C5 E1B-55K SUMOylation and virusinduced cell transformation

Wing-Hang Ip<sup>†</sup>, Marie Fiedler<sup>†</sup>, Britta Gornott, Malte Morische, Luca D. Bertzbach and Thomas Dobner<sup>\*</sup>

Department of Viral Transformation, Leibniz Institute of Virology (LIV), Hamburg, Germany

Various viral proteins are post-translationally modified by SUMO-conjugation during the human adenovirus (HAdV) replication cycle. This modification leads to diverse consequences for target proteins as it influences their intracellular localization or cell transformation capabilities. SUMOylated HAdV proteins include the multifunctional oncoprotein E1B-55K. Our previous research, along with that of others, has demonstrated a substantial influence of yet another adenoviral oncoprotein, E4orf6, on E1B-55K SUMOylation levels. Protein SUMOylation can be reversed by cellular sentrin/SUMO-specific proteases (SENPs). In this study, we investigated the interaction of E1B-55K with cellular SENPs to understand deSUMOylation activities and their consequences for cell transformation mediated by this adenoviral oncoprotein. We show that E1B-55K interacts with and is deSUMOylated by SENP 1, independently of E4orf6. Consistent with these results, we found that SENP 1 prevents E1A/E1Bdependent focus formation in rodent cells. We anticipate these findings to be the groundwork for future studies on adenovirus-host interactions, the mechanisms that underlie E1B-55K SUMOylation, as well as the role of this major adenoviral oncoprotein in HAdV-mediated cell transformation.

KEYWORDS

deSUMOylation, E4orf6, human adenovirus, oncogenes, post-translational modification, sentrin-specific protease (SENP), small ubiquitin-like modifier (SUMO), viral transformation

# **1** Introduction

Post-translational modifications (PTMs) remarkably diversify proteins in terms of protein maturation, function, localization, and adaptability (Sims and Reinberg, 2008; Beltrao et al., 2013). PTMs include a wide variety of protein modifications such as phosphorylation and acetylation, but also conjugation with proteins as in ubiquitination and SUMOylation pathways (Hochstrasser, 2009; Beltrao et al., 2013). Importantly, PTMs

are reversible and play key roles in virus infections, including infections with human adenoviruses (HAdVs) (Bergström Lind et al., 2013; Sohn et al., 2015; Wilson, 2017).

Research on PTMs of HAdV proteins, especially those by HAdV species C type 5 (HAdV-C5) has strongly improved our general understanding of the HAdV replication cycle and cellular transformation. Especially research on SUMOylation (that is, covalent conjugation of small ubiquitin-like modifier (SUMO) proteins) of HAdV proteins or HAdV-mediated SUMOylation of host cell proteins has recently gained momentum and revealed important new aspects of viral replication, virus-host cell interactions and virus-induced cell transformation (Everett et al., 2013; Sohn and Hearing, 2016; Fan et al., 2022; Ip et al., 2023b). Interestingly, SUMOylation of the multifunctional adenoviral large E1B protein E1B-55K determines its intracellular localization and consequently its transforming capacity, which occurs through the cooperation of adenoviral E1A proteins with E1B-55K as well as with the adenovirus E4 region-encoded oncoproteins E4orf6, E4orf3, and E4orf3/4 (Endter and Dobner, 2004; Kolbe et al., 2022; Ip et al., 2023a; Bertzbach et al., 2024). A single amino acid mutation at lysine 104 (K104) of the E1B-55K SUMO-conjugation motif has been shown to fully abrogate E1B-55K SUMOylation accompanied by a dramatic decrease in transformation efficiencies of rodent cells, suggesting that SUMOvlation and thus, intracellular localization of E1B-55K affect HAdV-mediated cell transformation (Endter et al., 2001; Kolbe et al., 2022; von Stromberg et al., 2023). In addition, a recently reported single amino acid mutation at a lysine in very close proximity to the main E1B-55K SUMO conjugation motif, lysine 101 (K101), has been shown to substantially increase E1B-55K SUMOylation accompanied by elevated nuclear localization of the protein (Kolbe et al., 2022). Consequences of the K101R mutation on HAdV-mediated cell transformation, however, remain largely elusive.

Likewise, a protein that is encoded in the E4 transcriptional unit is also known to interfere with the cellular SUMOylation machinery. The multifunctional protein E4orf6 acts as a regulatory factor for E1B-55K SUMOylation as it has been shown that E4orf6 deletion mutants have increased E1B-55K SUMOylation levels (Lethbridge et al., 2003). This E4orf6mediated reduction of E1B-55K SUMO levels is intriguing and we could recently show that their interaction is required for this process (Fiedler et al., 2022).

SUMOylation is facilitated by cellular (and viral) SUMO E3 ligases and constantly reversed by sentrin/SUMO-specific proteases (SENPs), a.k.a. SUMO proteases (Lowrey et al., 2017). To date, six human SUMO-deconjugating SENP isoforms are described, which are termed SENP 1, 2, 3, 5, 6, and 7. All six isoforms can proteolytically process and thereby "activate" SUMO proteins. Additionally, they also catalyze the deconjugation of SUMO proteins from substrate proteins (Yeh et al., 2000; Mukhopadhyay and Dasso, 2007; Hickey et al., 2012). These SENPs are classified into three groups depending on their sequences, evolutionary relationship, substrate proteins, and localization in the cell: SENP 1 and 2, SENP 3 and 5, and SENP 6 and 7 (Hickey et al., 2012; Kunz et al., 2018). Notably, SENP 4 is considered a pseudogene (Drag and Salvesen, 2008). In this study, we assessed the interaction of HAdV-C5 E1B-55K with cellular SENPs and investigated specific deSUMOylation activities. First, we show that E1B-55K interacts with SENP 1 and is deSUMOylated by SENP 1. Next, we determined the impact of SENP 1 in cooperation with E1A and E1B proteins on cell transformation and our data reveal an effective inhibition of E1A/E1B-dependent transformation by SENP 1-mediated deSUMOylation of E1B-55K. Finally, we demonstrate that this SENP 1-mediated reduction of E1B-55K SUMO levels occurs independently of E4orf6 expression.

# 2 Materials and methods

# 2.1 Cells and culture conditions

H1299 cells (ATCC no. CRL-5803; American Type Culture Collection; Manassas, VA, USA) and baby rat kidney (BRK) cells (Nevels et al., 1997; Speiseder et al., 2014) were kept in incubators at 37°C in a 5% CO<sub>2</sub> atmosphere and maintained in Dulbecco's modified Eagle medium (DMEM; Gibco; Carlsbad, CA, USA) with 10% fetal bovine serum (PAN Biotech; Aidenbach, Germany) and antibiotics (100 U penicillin/100  $\mu$ g streptomycin per ml, PAN Biotech). All cell lines were regularly monitored for mycoplasma contamination.

## 2.2 Plasmids and transient transfections

All recombinant plasmids were generated by site-directed mutagenesis using the vectors pcDNA3 and pCI-FLAG. SENPencoding plasmids (kindly provided by Dr. Stefan Müller), plasmids encoding 6x His SUMO 3 (Tatham et al., 2009), SUMO 3 Q90P (this work, forward primer 5'-GAT GTG TTC CAA CAG CCG ACG GGA GGT TAG-3', reverse primer 5'-CTA ACC TCC CGT CGG CTG TTG GAA CAC ATC-3'), HAdV-C5 E1B-55K (Nevels et al., 2001), the E1B-55K K101R and K104R mutants (Kolbe et al., 2022) and the HAdV-C5 E4orf6 (Querido et al., 2001) were used for transient polyethylenimine (PEI; Polysciences; Warrington, PA, USA) transfections (Schreiner et al., 2010).

## 2.3 Protein analyses

Transfected cell pellets were lysed on ice using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris/HCl pH 8, 150 mM NaCl, 5 mM EDTA, 1% P-40, 0.1% SDS, and 0.5% sodium deoxycholate). The lysates were then sonicated and centrifuged to remove cell debris. To investigate protein-protein interactions, one part of the resulting supernatant was immunoprecipitated for 2 h at 4°C followed by centrifugation at 600 × g for 5 min at 4°C exactly as described previously (Berscheminski et al., 2013). The remaining supernatant was boiled at 95°C for 5 minutes in 5% Laemmli buffer (input). Samples were stored at -20°C until further analyses by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS PAGE) and immunoblotting. For nickel-nitrilotriacetic acid (Ni-NTA) SUMO pulldown analyses, cells were harvested, washed with pre-cooled PBS, and lysed in guanidine hydrochloride (GuHCl) buffer (6 M Guanidinium-HCl, 10 mM Tris and 100 mM sodium phosphate buffer pH 8.0). His-SUMO modified proteins were coupled to the Ni-NTA agarose beads (Thermo Scientific) by incubation overnight at 4°C. Next, His-SUMO conjugates coupled to the Ni-NTA agarose were pelleted by centrifugation, washed, and His-SUMO conjugated proteins were eluted from the beads and stored at -20°C until further use (Tatham et al., 2009).

For immunoblotting, SDS PAGE-separated proteins were transferred to nitrocellulose membranes with a pore size of 45 µm (GE Healthcare; Chicago, IL, USA) via wet electroblotting using the TransBlot Electrophoretic Transfer Cell System (BioRad; Hercules, CA, USA). Next, membranes were incubated in 5% non-fat dry milk-PBS solution for 1 h at 4°C to saturate nonspecific antibody binding sites. The membranes were then washed 3 times with PBS-tween and incubated with the respective primary antibody at 4°C (Table 1). After 3 hours of incubation, membranes were washed and incubated with the respective horseradish peroxidase (HRP)-conjugated secondary antibody for 2 h at 4°C. Membranes were washed again and proteins were visualized on Xray films using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific; Waltham, MA, USA) according to the manufacturer's instructions. X-ray films were developed using the GBX Developer (Kodak; Rochester, NY, USA) and digitalized.

## 2.4 Transformation assays

BRK cells were seeded in 6-well plates and transfected with the respective plasmids with calcium phosphate following the manufacturer's protocol (ProFection Mammalian Transfection System, Promega; Madison, WI, USA). Transfected cells were cultivated for 4–8 weeks with weekly media changes until multilayered cell accumulations (foci) were visible. Foci were

TABLE 1 Antibodies.

Antibody	Concentration	Company or reference
Mouse mAb AC-15 (β-actin)	1:5,000	Sigma-Aldrich (St. Louis, MO, USA)
Mouse mAb 6x His (SUMO)	1:5,000	Clontech (Mountain View, CA, USA)
Mouse mAb M2 (FLAG)	1:2,000	Sigma-Aldrich
Mouse mAb 2A6 (E1B-55K)	1:10	(Sarnow et al., 1982)
Mouse mAb RSA3 (E4orf6)	1:10	(Marton et al., 1990)
HRP $\alpha$ -mouse IgG	1:10,000	Jackson (West Grove, PA, USA)

visualized by crystal violet staining and quantified in the same way as described previously (Speiseder et al., 2014). These experiments were repeated as four independent replicates.

## 2.5 Statistical analyses

Statistical analyses were performed using Graph-Pad Prism v9 (GraphPad Software, Inc.; La Jolla, CA, USA). A one-way analysis of variance with Dunnett's multiple comparisons test was used to analyze focus formation in BRK cells and data were considered significant if p values were  $\leq 0.05$ . Data are presented as means and error bars indicate standard deviations (SDs).

# **3** Results

# 3.1 E1B-55K interacts with and is deSUMOylated by SENP 1

To test if E1B-55K interacts with SENPs, we performed coimmunoprecipitation (co-IP) assays using plasmids expressing E1B-55K and catalytically inactive (CAT) FLAG-tagged SENP isoforms from all three SENP groups (SENPs 1, 2, 3, and 6). These catalytically inactive SENPs were used to elongate interactions between SENPs and E1B-55K as deSUMOylation is a quick process and consequently, interactions between SENPs and their targets are rather unstable (Kunz et al., 2018). E1B-55K precipitation and subsequent FLAGstaining revealed an interaction between SENP 1-CAT and E1B-55K, indicated by a SENP 1-CAT-specific band at 70 kDa (Figure 1A). Moreover, a rather faint band in SENP 3-CAT/E1B-55K cotransfections indicates their interaction. These results suggest that E1B-55K could be targeted for deSUMOvlation by SENP 1 and 3, although SENP 1 likely is the main SENP that deSUMOylates E1B-55K, given the much stronger staining (Figure 1A). In fact, SENP 6-CAT expression was very weak, and steady-state concentrations were not detectable (Figure 1A). On the other hand, SENP 1-CAT steadystate concentrations were also rather low, while the co-IP showed a solid enrichment of the protein (Figure 1A). These observations suggest that an interaction between E1B-55K and SENP6 is unlikely, but we have to note that it is difficult to make a definitive statement regarding the binding of E1B-55K to SENP 6. Collectively, however, our investigations on the interactions of E1B-55K with SENPs identified E1B-55K as a specific interaction partner of SENPs 1 and 3 (Figure 1A).

To assess the deSUMOylation of E1B-55K by SENP 1, we performed Ni-NTA pulldown analyses using H1299 cells that overexpress SUMO. We transfected these cells with different combinations of plasmids that express E1B-55K, SENP 1, and a catalytically inactive SENP 1 (SENP 1-CAT) (Figure 1B). Here, the His-SUMO pulldowns showed that SENP 1 reduced E1B-55K SUMO modification. At the same time, co-expression of the catalytically inactive mutant SENP 1-CAT did not affect SUMO modification of E1B-55K (Figure 1B).



#### FIGURE 1

E1B-55K interacts with and is deSUMOylated by SENP 1. (A) H1299 cells were transfected with plasmids that encode the indicated catalytically inactive FLAG-tagged SENP isoforms and E1B-55K. E1B-55K and E4orf6 alone, or in combination were included as controls. Immunoprecipitations of E1B-55K were performed with mAb 2A6 (E1B-55K), precipitates were resolved by SDS PAGE and visualized by immunoblotting. Co-precipitated proteins and input levels of total cell lysates were detected using mAb 2A6 (E1B-55K), mAb RSA3 (E4orf6), mAb M2 (FLAG), and mAb AC-15 (actin). (B) H1299 cells were transiently transfected with E1B-55K and FLAG-tagged SENP 1 or SENP 1-CAT-expressing plasmids. His-SUMO modified proteins were precipitated by Ni-NTA pulldown and total cell lysates were prepared. Precipitates and protein inputs were separated according to their molecular weight by SDS PAGE and visualized by immunoblotting. For specific protein detection, mAb 2A6 (E1B-55K), mAb M2 (FLAG), mAb 6x His (SUMO), and mAb AC-15 (actin) were used. Molecular weights in kDa are indicated on the left and the corresponding proteins are labeled on the right. Displayed are blots that are representative of >3 separate experiments.

# 3.2 SENP 1 overexpression results in efficient inhibition of E1A/E1B-dependent cell transformation

To investigate the effect of SENP 1 on E1A/E1B-dependent transformation of rodent cells in vitro, we transfected BRK cells with E1A and E1B-expressing plasmids alone or in combination with plasmids expressing active and inactive SENP 1. As controls for E1B-55K SUMOylation, either K104R (negative, mutation abrogates E1B-55K SUMOylation) or K101R (positive, mutation increases E1B-55K SUMOvlation) (Kolbe et al., 2022) were transfected in combination with E1A. Our transformation experiments confirmed that E1A and E1B expression result in efficient transformation of BRK cells (Figures 2A, B). E1A and K101R co-transfections induced a remarkably increased transformation rate, while E1B-55K almost lost its transforming capabilities upon introduction of the K104R mutation (Figure 2). Co-transfections of E1A and E1B-expressing plasmids with SENP 1 revealed that expression of SENP 1 causes a significant decrease in the foci numbers, indicating that SENP 1 inhibits E1Aand E1B-dependent transformation of BRK cells through efficient deSUMOylation of E1B-55K (Figure 2). Concomitantly, cotransfections of E1A and E1B with the catalytically inactive SENP 1 (SENP 1-CAT) restored focus formation to wild-type (wt) levels (Figure 2). In sum, these data confirm that deSUMOylation of E1B-55K is mediated by SENP 1, leading to strongly reduced proliferationpromoting features of this adenoviral multifactorial oncoprotein.

# 3.3 SENP 1-mediated E1B-55K deSUMOylation is E4orf6-independent

To determine if E4orf6 influences the interaction of E1B-55K with SENPs, both proteins were transfected into H1299 cells in combination with the SENP CAT isoforms 1 to 3 and 6, followed by immunoprecipitation assays (Figure 3A). These experiments showed that the binding of E1B-55K to SENPs was not abrogated by E4orf6 because E1B-55K still efficiently bound to SENP 1-CAT and rather weakly to SENP 3-CAT both in the presence (Figure 3A) or absence of E4orf6 (Figure 1). Further, our results suggest that E4orf6 does not recruit additional SENPs for E1B-55K deSUMOylation. However, it cannot be excluded that E4orf6 deSUMOylates E1B-55K independently of SENP 1. To test this, we used a SUMO mutant that harbors a glutamine (Q) to proline (P) mutation at its SENP-cleavage site at position 90 (Q90P) leading to structural changes within SUMO that prevent deSUMOylation by SENPs (Figure 3B) (Owerbach et al., 2005; Bekes et al., 2011). Upon transfection with wt E1B-55K and the hyper-SUMOylation mutant K101R without and with E4orf6, and after subsequent Ni-NTA pulldowns, we found that co-transfection of E4orf6 resulted in reduced SUMO levels of E1B-55K and K101R (Figure 3B). Similar to wt SUMO, Q90P was conjugated to E1B-55K and K101R (Figure 3B), and Q90P-conjugation to E1B-55K and K101R were also decreased in presence of E4orf6 (Figure 3B). Thus, we confirmed that SENP 1 reduces SUMO on E1B-55K and demonstrate that this process can be, in part, compensated by E4orf6.



#### FIGURE 2

SENP 1 averts cell transformation, which is highly increased in HAdV-C5 E1B-55K K101R-transfected BRK cells. (A) BRK cells were transfected with plasmids encoding E1A alone or in combination with wt E1B-55K, K101R, or K104R. SENP 1 or SENP 1-CAT were transfected alone or together with E1A and E1B as indicated. sssDNA was transfected as DNA carrier. The cells were kept in culture for eight weeks before the plates were fixed and stained with a crystal violet solution. The illustration shows one representative experiment of four repeated assays. (B) Foci of each plate were quantified and plotted, and the error bars show the SD. Asterisks indicate significant differences (p-values were obtained from a one-way ANOVA with a Dunnett's multiple comparisons test (\*p  $\leq$  0.05, \*\*\*\*p  $\leq$  0.0001), comparing data to 'E1A + E1B'). sssDNA: sheared salmon sperm DNA.

# 4 Discussion

The adenoviral E1B-55K oncoprotein is a key player in various processes during the viral replication cycle and for viral transformation (Blackford and Grand, 2009; Hidalgo et al., 2019). E1B-55K is SUMO-modified, a process that is negatively regulated by another adenoviral oncoprotein, E4orf6. While recent research focused on E1B-55K SUMOylation, its deSUMOylation through cellular proteins, i.e. the reversion by SUMO-specific proteases, remained elusive. In this report, we present SENP 1 as the protease that deSUMOylates E1B-55K and substantiate these data by a strong reduction of E1B-55K-mediated cell transformation upon SENP 1 overexpression.

We first demonstrated that E1B-55K interacts with and is deSUMOylated by SENP 1. These findings, consistent with previous observations showing the deSUMOylation of Kap1 by SENP 1 (Li et al., 2007; Bürck et al., 2016), support the hypothesis that functionally related protein groups are targeted by the same SENPs (Psakhye and Jentsch, 2012; Jentsch and Psakhye, 2013).

Next, we demonstrated that SENP 1 overexpression efficiently inhibits E1A/E1B-dependent cell transformation. It is wellestablished that E1A/E1B-induced transformation of rodent cells occurs through repression of p53-stimulated transcription, a characteristic of HAdVs (Yew and Berk, 1992; von Stromberg et al., 2023; Bertzbach et al., 2024). Our findings reveal that (i) SENP 1-



M2 (FLAG), mAb 6x His (SUMO) and mAb AC-15 (actin). Molecular weights in kDa are indicated on the left and the corresponding proteins are labeled on the right. Displayed are blots that are representative of >3 separate experiments.

mediated deSUMOylation of E1B-55K reduces its ability to form foci, and (ii) the high SUMOylation of the K101R variant is associated with a "gain-of-function," leading to increased repression of p53stimulated transcription (Kolbe et al., 2022; von Stromberg et al., 2023) and, consequently, increased focus formation in BRK cells.

Finally, our data show that E4orf6 can partially compensate for the SENP1-mediated deSUMOylation of E1B-55K. Interestingly, a recent report characterized the impact of E4orf6 on the expression of SENP 8. In contrast to the other SENPs, this cysteine protease is not involved in deSUMOylation but deconjugates the ubiquitin-like protein NEDD8 from target proteins. This deNEDDylase is downregulated by E4orf6, resulting in an increased NEDDylation of cullin 5, which in turn suppressed p53 degradation (Guo et al., 2019). Our data indicate that, in addition to ubiquitination, and NEDDylation, E4orf6 also plays a role in regulating another PTM: protein SUMOylation. These and our findings extend the list of E4orf6 functions (Ohman et al., 1993; Nordqvist et al., 1994; Dobner et al., 1996; Jayaram et al., 2008; Müller et al., 2012).

In addition, the interactions between E1B-55K and SENP 1 could possibly manipulate nuclear import and export processes to favor the transport of viral late mRNAs and late viral proteins (Woo and Berk, 2007; Blanchette et al., 2008). SENPs 1 and 2 have been shown to be involved in nuclear pore complex integrity (Hang and Dasso, 2002; Zhang et al., 2002; Goeres et al., 2011; Chow et al., 2014) and one could speculate that binding to viral proteins could alter their function and thereby modulate the functionality of the nuclear pore complex. In sum, our results further link the SUMO-conjugation machinery with adenovirus-induced cell transformation and highlight new aspects of the interaction of adenoviral oncoproteins with regulatory host enzymes. Future work could include infection of SENP knockdown or knockout cells to further understand consequences of these interactions.

# Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

# Author contributions

W-HI: Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. MF: Conceptualization, Formal analysis, Investigation, Writing – review & editing. BG: Investigation, Writing – review & editing. MM: Writing – review & editing, Investigation. LDB: Formal analysis, Writing – review & editing, Visualization, Writing – original draft. TD: Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – review & editing.

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The LV receives financial support from the Freie und Hansestadt Hamburg and the German Bundesministerium für Gesundheit (BMG).

# Acknowledgments

We thank Dr. Stefan Müller (Goethe Universität in Frankfurt a. M.) for providing the SENP-encoding plasmids and Dr. Ronald T. Hay (University of Dundee) for supplying the SUMO plasmid.

# References

Bekes, M., Prudden, J., Srikumar, T., Raught, B., Boddy, M. N., and Salvesen, G. S. (2011). The dynamics and mechanism of sumo chain deconjugation by sumo-specific proteases. *J. Biol. Chem.* 286, 10238–10247. doi: 10.1074/jbc.M110.205153

Beltrao, P., Bork, P., Krogan, N. J., and van Noort, V. (2013). Evolution and functional cross-talk of protein post-translational modifications. *Mol. Syst. Biol.* 9, 714. doi: 10.1002/msb.201304521

Bergström Lind, S., Artemenko, K. A., Elfineh, L., Zhao, Y., Bergquist, J., and Pettersson, U. (2013). Post translational modifications in adenovirus type 2. *Virology* 447, 104–111. doi: 10.1016/j.virol.2013.08.033

Berscheminski, J., Groitl, P., Dobner, T., Wimmer, P., and Schreiner, S. (2013). The adenoviral oncogene E1a-13s interacts with a specific isoform of the tumor suppressor pml to enhance viral transcription. *J. Virol.* 87, 965–977. doi: 10.1128/JVI.02023-12

Bertzbach, L. D., Ip, W. H., von Stromberg, K., Dobner, T., and Grand, R. J. (2024). A comparative review of adenovirus A12 and C5 oncogenes. *Curr. Opin. Virol.* 67, 101413. doi: 10.1016/j.coviro.2024.101413

Blackford, A. N., and Grand, R. J. (2009). Adenovirus E1b 55-kilodalton protein: multiple roles in viral infection and cell transformation. *J. Virol.* 83, 4000–4012. doi: 10.1128/JVI.02417-08

Blanchette, P., Kindsmüller, K., Groitl, P., Dallaire, F., Speiseder, T., Branton, P. E., et al. (2008). Control of mrna export by adenovirus E4orf6 and E1b55k proteins during productive infection requires E4orf6 ubiquitin ligase activity. *J. Virol.* 82, 2642–2651. doi: 10.1128/JVI.02309-07

Bürck, C., Mund, A., Berscheminski, J., Kieweg, L., Müncheberg, S., Dobner, T., et al. (2016). Kap1 is a host restriction factor that promotes human adenovirus E1b-55k sumo modification. *J. Virol.* 90, 930–946. doi: 10.1128/JVI.01836-15

Chow, K. H., Elgort, S., Dasso, M., Powers, M. A., and Ullman, K. S. (2014). The sumo proteases senp1 and senp2 play a critical role in nucleoporin homeostasis and nuclear pore complex function. *Mol. Biol. Cell* 25, 160–168. doi: 10.1091/mbc.E13-05-0256

Dobner, T., Horikoshi, N., Rubenwolf, S., and Shenk, T. (1996). Blockage by adenovirus E4orf6 of transcriptional activation by the P53 tumor suppressor. *Science* 272, 1470–1473. doi: 10.1126/science.272.5267.1470

Drag, M., and Salvesen, G. S. (2008). Desumoylating enzymes-senps. *IUBMB Life* 60, 734-742. doi: 10.1002/iub.113

Endter, C., and Dobner, T. (2004). Cell transformation by human adenoviruses. Curr. Top. Microbiol. Immunol. 273, 163–214. doi: 10.1007/978-3-662-05599-1\_6

Endter, C., Kzhyshkowska, J., Stauber, R., and Dobner, T. (2001). Sumo-1 modification required for transformation by adenovirus type 5 early region 1b 55-kda oncoprotein. *Proc. Natl. Acad. Sci. U.S.A.* 98, 11312–11317. doi: 10.1073/pnas.191361798

Everett, R. D., Boutell, C., and Hale, B. G. (2013). Interplay between viruses and host sumoylation pathways. *Nat. Rev. Microbiol.* 11, 400–411. doi: 10.1038/nrmicro3015

Fan, Y., Li, X., Zhang, L., Zong, Z., Wang, F., Huang, J., et al. (2022). SUMOylation in viral replication and antiviral defense. *Adv. Sci. (Weinh)*. 9:e2104126. doi: 10.1002/advs.202104126

Fiedler, M., Ip, W. H., Hofmann-Sieber, H., Wilkens, B., Nkrumah, F. K., Zhang, W., et al. (2022). Protein–protein interactions facilitate E4orf6-dependent regulation of E1b-55k sumoylation in hadv-C5 infection. *Viruses* 14, 463. doi: 10.3390/v14030463

Goeres, J., Chan, P. K., Mukhopadhyay, D., Zhang, H., Raught, B., and Matunis, M. J. (2011). The sumo-specific isopeptidase senp2 associates dynamically with nuclear pore

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

complexes through interactions with karyopherins and the nup107-160 nucleoporin subcomplex. *Mol. Biol. Cell* 22, 4868–4882. doi: 10.1091/mbc.E10-12-0953

Guo, H., Shen, S., Li, Y., Bi, R., Zhang, N., Zheng, W., et al. (2019). Adenovirus oncoprotein E40rf6 triggers cullin5 neddylation to activate the clr5 E3 ligase for P53 degradation. *Biochem. Biophys. Res. Commun.* 516, 1242–1247. doi: 10.1016/j.bbrc.2019.07.028

Hang, J., and Dasso, M. (2002). Association of the human sumo-1 protease senp2 with the nuclear pore. J. Biol. Chem. 277, 19961–19966. doi: 10.1074/jbc.M201799200

Hickey, C. M., Wilson, N. R., and Hochstrasser, M. (2012). Function and regulation of sumo proteases. *Nat. Rev. Mol. Cell Biol.* 13, 755–766. doi: 10.1038/nrm3478

Hidalgo, P., Ip, W. H., Dobner, T., and Gonzalez, R. A. (2019). The biology of the adenovirus E1b 55k protein. *FEBS Lett.* 593, 3504–3517. doi: 10.1002/1873-3468.13694

Hochstrasser, M. (2009). Origin and function of ubiquitin-like proteins. *Nature* 458, 422–429. doi: 10.1038/nature07958

Ip, W. H., Bertzbach, L. D., Speiseder, T., and Dobner, T. (2023a). The adenoviral E4orf3/4 is a regulatory polypeptide with cell transforming properties *in vitro*. *Tumour Virus Res.* 15, 200254. doi: 10.1016/j.tvr.2023.200254

Ip, W. H., Tatham, M. H., Krohne, S., Gruhne, J., Melling, M., Meyer, T., et al. (2023b). Adenovirus E1b-55k controls sumo-dependent degradation of antiviral cellular restriction factors. *J. Virol.* 97, e0079123. doi: 10.1128/jvi.00791-23

Jayaram, S., Gilson, T., Ehrlich, E. S., Yu, X. F., Ketner, G., and Hanakahi, L. (2008). E1b 55k-independent dissociation of the DNA ligase iv/xrcc4 complex by E4 34k during adenovirus infection. *Virology* 382, 163–170. doi: 10.1016/j.virol.2008.08.045

Jentsch, S., and Psakhye, I. (2013). Control of nuclear activities by substrate-selective and protein-group sumoylation. *Annu. Rev. Genet.* 47, 167–186. doi: 10.1146/annurev-genet-111212-133453

Kolbe, V., Ip, W. H., Kieweg-Thompson, L., Lang, J., Gruhne, J., Meyer, T., et al. (2022). Conserved E1b-55k sumoylation in different human adenovirus species is a potent regulator of intracellular localization. *J. Virol.* 96, e0083821. doi: 10.1128/JVI.00838-21

Kunz, K., Piller, T., and Müller, S. (2018). Sumo-specific proteases and isopeptidases of the senp family at a glance. J. Cell Sci. 131, jcs211904. doi: 10.1242/jcs.211904

Lethbridge, K. J., Scott, G. E., and Leppard, K. N. (2003). Nuclear matrix localization and sumo-1 modification of adenovirus type 5 E1b 55k protein are controlled by E4 orf6 protein. *J. Gen. Virol.* 84, 259–268. doi: 10.1099/vir.0.18820-0

Li, X., Lee, Y. K., Jeng, J. C., Yen, Y., Schultz, D. C., Shih, H. M., et al. (2007). Role for kap1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating kap1-mediated transcriptional repression. *J. Biol. Chem.* 282, 36177–36189. doi: 10.1074/jbc.M706912200

Lowrey, A. J., Cramblet, W., and Bentz, G. L. (2017). Viral manipulation of the cellular sumoylation machinery. *Cell Commun. Signal* 15, 27. doi: 10.1186/s12964-017-0183-0

Marton, M. J., Baim, S. B., Ornelles, D. A., and Shenk, T. (1990). The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2f, altering its DNA-binding properties and stimulating E1a-independent accumulation of E2 mrna. *J. Virol.* 64, 2345–2359. doi: 10.1128/JVI.64.5.2345-2359.1990

Mukhopadhyay, D., and Dasso, M. (2007). Modification in reverse: the sumo proteases. *Trends Biochem. Sci.* 32, 286–295. doi: 10.1016/j.tibs.2007.05.002

Müller, D., Schreiner, S., Schmid, M., Groitl, P., Winkler, M., and Dobner, T. (2012). Functional cooperation between human adenovirus type 5 early region 4, open reading frame 6 protein, and cellular homeobox protein hoxb7. J. Virol. 86, 8296-8308. doi: 10.1128/JVI.00222-12

Nevels, M., Rubenwolf, S., Spruss, T., Wolf, H., and Dobner, T. (1997). The adenovirus E4orf6 protein can promote E1a/E1b-induced focus formation by interfering with P53 tumor suppressor function. *Proc. Natl. Acad. Sci. U.S.A.* 94, 1206–1211. doi: 10.1073/pnas.94.4.1206

Nevels, M., Tauber, B., Spruss, T., Wolf, H., and Dobner, T. (2001). Hit-and-run" Transformation by adenovirus oncogenes. J. Virol. 75, 3089–3094. doi: 10.1128/ JVI.75.7.3089-3094.2001

Nordqvist, K., Ohman, K., and Akusjarvi, G. (1994). Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mrnas. *Mol. Cell Biol.* 14, 437–445. doi: 10.1128/mcb.14.1.437

Ohman, K., Nordqvist, K., and Akusjarvi, G. (1993). Two adenovirus proteins with redundant activities in virus growth facilitates tripartite leader mrna accumulation. *Virology* 194, 50–58. doi: 10.1006/viro.1993.1234

Owerbach, D., McKay, E. M., Yeh, E. T., Gabbay, K. H., and Bohren, K. M. (2005). A proline-90 residue unique to sumo-4 prevents maturation and sumoylation. *Biochem. Biophys. Res. Commun.* 337, 517–520. doi: 10.1016/j.bbrc.2005.09.090

Psakhye, I., and Jentsch, S. (2012). Protein group modification and synergy in the sumo pathway as exemplified in DNA repair. *Cell* 151, 807–820. doi: 10.1016/j.cell.2012.10.021

Querido, E., Morrison, M. R., Chu-Pham-Dang, H., Thirlwell, S. W., Boivin, D., and Branton, P. E. (2001). Identification of three functions of the adenovirus E4orf6 protein that mediate P53 degradation by the E4orf6-E1b55k complex. *J. Virol.* 75, 699–709. doi: 10.1128/JVI.75.2.699-709.2001

Sarnow, P., Sullivan, C. A., and Levine, A. J. (1982). A monoclonal antibody detecting the adenovirus type 5 E 1 B-58kd tumor antigen: characterization of the E 1 B-58kd tumor antigen in adenovirus-infected and -transformed cells. *Virology* 120, 510–517. doi: 10.1016/0042-6822(82)90054-x

Schreiner, S., Wimmer, P., Sirma, H., Everett, R. D., Blanchette, P., Groitl, P., et al. (2010). Proteasome-dependent degradation of daxx by the viral E1b-55k

protein in human adenovirus-infected cells. J. Virol. 84, 7029–7038. doi: 10.1128/ JVI.00074-10

Sims, R. J. 3rd, and Reinberg, D. (2008). Is there a code embedded in proteins that is based on post-translational modifications? *Nat. Rev. Mol. Cell Biol.* 9, 815–820. doi: 10.1038/nrm2502

Sohn, S. Y., Bridges, R. G., and Hearing, P. (2015). Proteomic analysis of ubiquitinlike posttranslational modifications induced by the adenovirus E4-orf3 protein. *J. Virol.* 89, 1744–1755. doi: 10.1128/JVI.02892-14

Sohn, S. Y., and Hearing, P. (2016). Adenovirus early proteins and host sumoylation. *mBio* 7, e01154–16–7. doi: 10.1128/mBio.01154-16

Speiseder, T., Nevels, M., and Dobner, T. (2014). Determination of the transforming activities of adenovirus oncogenes. *Methods Mol. Biol.* 1089, 105–115. doi: 10.1007/978-1-62703-679-5\_8

Tatham, M. H., Rodriguez, M. S., Xirodimas, D. P., and Hay, R. T. (2009). Detection of protein sumoylation in vivo. *Nat. Protoc.* 4, 1363–1371. doi: 10.1038/nprot.2009.128

von Stromberg, K., Seddar, L., Ip, W. H., Günther, T., Gornott, B., Weinert, S. C., et al. (2023). The human adenovirus E1b-55k oncoprotein coordinates cell transformation through regulation of DNA-bound host transcription factors. *Proc. Natl. Acad. Sci. U.S.A.* 120, e2310770120. doi: 10.1073/pnas.2310770120

Wilson, V. G. (2017). Viral interplay with the host sumoylation system. Adv. Exp. Med. Biol. 963, 359–388. doi: 10.1007/978-3-319-50044-7\_21

Woo, J. L., and Berk, A. J. (2007). Adenovirus ubiquitin-protein ligase stimulates viral late mrna nuclear export. J. Virol. 81, 575–587. doi: 10.1128/JVI.01725-06

Yeh, E. T., Gong, L., and Kamitani, T. (2000). Ubiquitin-like proteins: new wines in new bottles. *Gene* 248, 1–14. doi: 10.1016/s0378-1119(00)00139-6

Yew, P. R., and Berk, A. J. (1992). Inhibition of P53 transactivation required for transformation by adenovirus early 1b protein. *Nature* 357, 82–85. doi: 10.1038/357082a0

Zhang, H., Saitoh, H., and Matunis, M. J. (2002). Enzymes of the sumo modification pathway localize to filaments of the nuclear pore complex. *Mol. Cell Biol.* 22, 6498–6508. doi: 10.1128/mcb.22.18.6498-6508.2002